CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $366,298, lower than 95% of all stocks globally
- PositionGross margin is -0.6%, lower than 95% of its Medical Devices peers (median 59.2%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
56.73BTWD1.78B · vs all stocks (USD)
Revenue (TTM)
11.69MTWD366.30K · vs all stocks (USD)
Profit Margin
-250.12%vs Medical Devices peers
52-Week Change
-58.65%vs all stocks
Market Capitalization
56.73BTWD1.78B · vs all stocks (USD)
Enterprise Value
50.78BTWD1.59B · vs all stocks (USD)
Forward P/E
53.28xvs Medical Devices peers
Price to Book (MRQ)
5.37xvs Medical Devices peers
Enterprise to Revenue
4.34Kxvs Medical Devices peers
Enterprise to EBITDA
-89.78xvs Medical Devices peers
Gross Margin
-0.59%vs Medical Devices peers
Profit Margin
-250.12%vs Medical Devices peers
Return on Assets (TTM)
-5.75%vs Medical Devices peers
Return on Equity (TTM)
-7.67%vs Medical Devices peers
Revenue (TTM)
11.69MTWD366.30K · vs all stocks (USD)
Revenue per Share (TTM)
0.0760TWDUpdated Aug 21, 2026Quarterly Revenue Growth
-71.70%vs Medical Devices peers
Gross Profit (TTM)
-18.00MTWD-563.94K · vs all stocks (USD)
EBITDA (TTM)
-565.60MTWD-17.72M · vs all stocks (USD)
Net Income (TTM)
-479.38MTWD-15.02M · vs all stocks (USD)
Operating Cash Flow (TTM)
-677.60MTWD-21.23M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-611.75MTWD-19.17M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
10.31MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
36.09MTWDFY2025 · Dec 31, 2025Gross Profit
-25.78MTWDFY2025 · Dec 31, 2025Operating Income
-534.32MTWD-16.74M · vs all stocks (USD)
Pre-tax Income
-481.67MTWDFY2025 · Dec 31, 2025Income Tax Expense
0.00TWDFY2025 · Dec 31, 2025Net Income
-481.67MTWDFY2025 · Dec 31, 2025EBIT
-480.78MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-441.15MTWDFY2025 · Dec 31, 2025Research & Development
321.87MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
186.68MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
46.19MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
887.00KTWDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-481.67MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-431.02MTWDFY2025 · Dec 31, 2025Free Cash Flow
-458.82MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.35BTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-481.67MTWDFY2025 · Dec 31, 2025Stock-based Compensation
161.83MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-45.30MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.08MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-60.80MTWDFY2025 · Dec 31, 2025Capital Expenditures
-27.81MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.27MTWDFY2025 · Dec 31, 2025Purchase of Investments
-8.73BTWDFY2025 · Dec 31, 2025Other Investing Activity
2.00MTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.76BTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
10.88BTWDFY2025 · Dec 31, 2025Shares Outstanding
157.68MSharesUpdated Aug 21, 2026Float Shares
51.64MSharesUpdated Aug 21, 2026% Held by Insiders
68.48%vs all stocks
% Held by Institutions
3.75%vs all stocks
Total Cash (MRQ)
9.42BTWD295.08M · vs all stocks (USD)
Total Cash per Share (MRQ)
59.60TWDUpdated Aug 21, 2026Total Debt (MRQ)
235.86MTWD7.39M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0211xvs Medical Devices peers
Current Ratio (MRQ)
135.76xvs Medical Devices peers
Book Value per Share (MRQ)
70.67TWDUpdated Aug 21, 2026Total Assets
11.58BTWD362.84M · vs all stocks (USD)
Total Current Assets
10.55BTWDFY2025 · Dec 31, 2025Total Liabilities
89.30MTWDFY2025 · Dec 31, 2025Total Non-current Assets
1.03BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
24.53MTWDFY2025 · Dec 31, 2025Total Current Liabilities
64.78MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.35BTWDFY2025 · Dec 31, 2025Other Short-term Investments
7.88BTWDFY2025 · Dec 31, 2025Accounts Receivable
331.00KTWDFY2025 · Dec 31, 2025Inventory
67.34MTWDFY2025 · Dec 31, 2025Accounts Payable
13.26MTWDFY2025 · Dec 31, 2025Short-term Debt
5.54MTWDFY2025 · Dec 31, 2025Other Current Liabilities
420.00KTWDFY2025 · Dec 31, 2025Long-term Debt
1.69MTWDFY2025 · Dec 31, 2025Common Stock (Book)
1.58BTWDFY2025 · Dec 31, 2025Retained Earnings
-481.67MTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
11.49BTWD360.04M · vs all stocks (USD)
52-Week Low
300.00TWDUpdated Aug 21, 202652-Week High
932.00TWDUpdated Aug 21, 202652-Week Change
-58.65%vs all stocks
50-Day MA
384.21TWDUpdated Aug 21, 2026200-Day MA
430.68TWDUpdated Aug 21, 2026Avg 10-Day Volume
216.52KSharesUpdated Aug 21, 2026Avg 30-Day Volume
503.16KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-3.34TWDUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -0.6%, lower than 95% of its Medical Devices peers (median 59.2%)Significant
Gross margin: -0.01Industry median: 0.59Industry P5: 0.24Peers compared: 59.00
Operating margin is -28243.9%, lower than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: -282.439Industry median: 0.07Industry P5: -0.52Peers compared: 59.00
Profit margin is -250.1%, lower than 95% of its Medical Devices peers (median 3.6%)Significant
Profit margin: -2.50Industry median: 0.04Industry P5: -0.90Peers compared: 59.00
Current ratio is 135.76×, higher than 95% of its Medical Devices peers (median 2.76×)Significant
Current ratio: 135.757Industry median: 2.76Industry P95: 8.20Peers compared: 59.00
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $366,298, lower than 95% of all stocks globallySignificant
Revenue (USD): 366,298.193Global P5: 30,274,777.221
Market cap is $1.78B, above the global median of $1.15BNotable
Market cap (USD): 1,777,774,098.053Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Precigen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shyndec Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Liaoning Chengda Biotechnology Co., Ltd.
4 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDown-Close Share With Multi-Year Earnings DecreaseLow-Leverage Liquidity ConfigurationLiquidity Ratios Elevated
Wuhan Fingu Electronic Technology Co., Ltd.
4 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDown-Close Share With Multi-Year Earnings DecreaseLow-Leverage Liquidity ConfigurationLiquidity Ratios Elevated
Jiangsu Topfly New Material Co. Ltd.
4 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDown-Close Share With Multi-Year Earnings DecreaseLow-Leverage Liquidity ConfigurationLiquidity Ratios Elevated